Access the full text.
Sign up today, get DeepDyve free for 14 days.
O. Lowry, N. Rosebrough, A. Farr, R. Randall (1951)
Protein measurement with the Folin phenol reagent.The Journal of biological chemistry, 193 1
H. Ohkawa, N. Ohishi, K. Yagi (1979)
Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction.Analytical biochemistry, 95 2
P. Riederer, W. Rausch, B. Schmidt, P. Kruzik, C. Konradi, E. Sofić, W. Danielczyk, M. Fischer, E. Ogris (1988)
Biochemical fundamentals of Parkinson's disease.The Mount Sinai journal of medicine, New York, 55 1
Grahame-Smith Dg (1984)
Catecholamine toxicity : a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's diseaseNeurotoxicology, 5
D. Graham (1978)
Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.Molecular pharmacology, 14 4
Ambani Lm, Van Mh, S. Murphy (1975)
Brain peroxidase and catalase in Parkinson disease.Archives of neurology, 32 2
J. MacGee (1959)
Enzymatic determination of polyunsaturated fatty acids.Analytical Chemistry, 31
K. Earle (1968)
Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue.Journal of neuropathology and experimental neurology, 27 1
D. Graham, S. Tiffany, W. Bell, W. Gutknecht (1978)
Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro.Molecular pharmacology, 14 4
J. Folch, M. Lees, G. Stanley (1957)
A simple method for the isolation and purification of total lipides from animal tissues.The Journal of biological chemistry, 226 1
P. Riederer, E. Sofic, W. Rausch, P. Kruzik, M. Youdim (1985)
Dopaminforschung heute und morgen - L-Dopa in der Zukunft
I. Vyas, R. Heikkila, W. Nicklas (1986)
Studies on the Neurotoxicity of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine: Inhibition of NAD‐Linked Substrate Oxidation by Its Metabolite, 1‐Methyl‐4‐PhenylpyridiniumJournal of Neurochemistry, 46
I. Kopin, S. Burns, C. Chiueh, S. Markey (1986)
MPTP-Induced Parkinsonian Syndromes in Humans and Animals
T. Perry, V. Yong (1986)
Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patientsNeuroscience Letters, 67
B. Sinha, Y. Singh, G. Krishna (1986)
Formation of superoxide and hydroxyl radicals from 1-methyl-4-phenylpyridinium ion (MPP+): reductive activation by NADPH cytochrome P-450 reductase.Biochemical and biophysical research communications, 135 2
T. Perry, D. Godin, S. Hansen (1982)
Parkinson's disease: A disorder due to nigral glutathione deficiency?Neuroscience Letters, 33
S. Rehncrona, David Smith, B. Åkesson, E. Westerberg, B. Siesjö (1980)
Peroxidative Changes in Brain Cortical Fatty Acids and Phospholipids, as Characterized During Fe2+‐ and Ascorbic Acid‐Stimulated Lipid Peroxidation In VitroJournal of Neurochemistry, 34
D. Dexter, C. Carter, F. Agid, Y. Agid, A. Lees, P. Jenner, C. Marsden (1986)
LIPID PEROXIDATION AS CAUSE OF NIGRAL CELL DEATH IN PARKINSON'S DISEASEThe Lancet, 328
M. Weller, S. Rose, P. Jenner, C. Marsden (1987)
in vitro characterisation of dopamine receptors in the superior colliculus of the ratNeuropharmacology, 26
(1975)
Uneven prevalence of Parkinson's disease in the province of Quebec. Can
S. Kish, Caryl Morito, O. Hornykiewicz (1986)
Brain glutathione peroxidase in neurodegenerative disorders.Neurochemical pathology, 4 1
F. Hefti, E. Melamed, J. Bhawan, R. Wurtman (1981)
Long‐term administration of L‐DOPA does not damage dopaminergic neurons in the mouseNeurology, 31
D. Dexter, F. Wells, F. Agid, Y. Agid, A. Lees, P. Jenner, C. Marsden (1987)
INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAINThe Lancet, 330
B. Halliwell, J. Gutteridge (1985)
Free radicals in biology and medicine
Abstract: Polyunsaturated fatty acid (PUFA) levels (an index of the amount of substrate available for lipid peroxidation) were measured in several brain regions from patients who died with Parkinson's disease and age‐matched control human postmortem brains. PUFA levels were reduced in parkinsonian substantia nigra compared to other brain regions and to control tissue. However, basal malondialdehyde (MDA; an intermediate in the lipid peroxidation process) levels were increased in parkinsonian nigra compared with other parkinsonian brain regions and control tissue. Expressing basal MDA levels in terms of PUFA content, the difference between parkinsonian and control substantia nigra was even more pronounced. Stimulating MDA production by incubating tissue with FeSO4 plus ascorbic acid, FeSO4 plus H2O2, or air alone produced lower MDA levels in the parkinsonian substantia nigra, probably reflecting the lower PUFA content. These results may indicate that an increased level of lipid peroxidation continues to occur in the parkinsonian nigra up to the time of death, perhaps because of continued exposure to excess free radicals derived from some endogenous or exogenous neurotoxic species.
Journal of Neurochemistry – Wiley
Published: Feb 1, 1989
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.